Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled Study Comparing the Safety and Analgesic Efficacy of ABT-110 to Placebo in Subjects with Pain from Osteoarthritis of the Knee
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Mar 2013
Price :
$35
*
At a glance
- Drugs ABT 110 (Primary)
- Indications Musculoskeletal pain; Osteoarthritis
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- Sponsors Abbott GmbH & Co. KG
- 26 Jan 2013 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
- 22 Sep 2012 Planned End Date changed from 29 Jul 2013 to 2 Dec 2013 as reported by European Clinical Trials Database record.
- 14 Jul 2012 Actual initiation date changed from 29 Mar 2012 to 2 Jul 2012, as reported by European Clinical Trials Database.